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Original Article
Purpose: The purpose of this study was to assess the clinical outcomes of hypofractionated radiotherapy (HFRT) with three-
dimensional conformal technique for medically inoperable patients with early stage non-small-cell lung cancer (NSCLC) and to 
evaluate prognostic factors.
Materials and Methods: We performed a retrospective review of 26 patients who underwent HFRT for early stage NSCLC 
between September 2005 and August 2011. Only clinical stage T1-3N0 was included. The median RT dose was 70 Gy (range, 60 
to 72 Gy) and the median biologically equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of patients, 4 Gy per 
fraction was used. Neoadjuvant chemotherapy with paclitaxel and cisplatin was given to 2 of 26 patients.
Results: The median follow-up time for surviving patients was 21 months (range, 13 to 49 months). The overall response rate was 
53.9%, and the initial local control rate was 100%. The median survival duration was 27.8 months. Rates of 2-year overall survival, 
progression-free survival (PFS), local control (LC), and locoregional-free survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, 
respectively. Multivariate analysis showed that BED (>90 vs. ≤90 Gy) was an independent prognostic factor influencing PFS, LC, and 
LRFS. Severe toxicities over grade 3 were not observed.
Conclusion: Radical HFRT can yield satisfactory disease control with acceptable rates of toxicities in medically inoperable patients 
with early stage NSCLC. HFRT is a viable alternative for clinics and patients ineligible for stereotactic ablative radiotherapy. BED over 
90 Gy and 4 Gy per fraction might be appropriate for HFRT.
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Introduction
Surgical resection with lobectomy is the treatment of choice 
for early stage non-small-cell lung cancer (NSCLC) [1]. 
However, this surgical option is limited to a small proportion 
of NSCLC cases due to perioperative mortality, poor medical 
condition, and patient refusal [1]. Historically, radical 
radiotherapy has been an alternative option for patients who 
cannot undergo surgery. However, conventional fractionated 
radiotherapy with 60 to 66 Gy in 1.8- or 2-Gy fractions results 
in poor outcomes with about 50% local control and about 
20% to 30% overall survival rate at 3 years [2,3].
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One way to improve the outcomes of radial radiotherapy 
alone is to escalate the radiation dose. However, escalating 
the dose with conventional fractionation leads to protracted 
treatment, resulting in increased cost, inconvenience, and the 
risk of tumor repopulation [4,5]. In contrast, a hypofractionated 
regimen can intensify the radiation dose as well as shorten 
the overall treatment duration. Although the radiobiological 
benefit of hypofractionation is well known, increases in late 
toxicities can restrict its use. Three-dimensional conformal 
radiation therapy (3D-CRT) allows the formulation of 
a complex multiple-field plan, and makes it possible to 
protect normal tissue from high doses of radiotherapy, 
while maintaining target coverage. The recently introduced 
stereotactic ablative radiotherapy (SABR) regimen yields high 
local control rates (85-95%) and acceptable toxicities in early 
stage NSCLC [6-8].
However, SABR requires levels of precision and accuracy 
that surpass the requirements of conventionally fractionated 
radiation therapy or intensity-modulated delivery. Strict 
protocols must be followed for quality assurance that require 
expensive treatment equipment and highly qualified human 
resources [9], which makes it impractical for small-sized cancer 
centers. Hypofractionated radiotherapy (HFRT) using 3D-CRT 
can be considered as the second policy in clinics and patients 
ineligible for SABR. Some studies of HFRT using various 
radiation dose schedules resulted in improved outcomes 
beyond those achieved with conventionally fractionated 
radiotherapy [10-14]. Thus, the purpose of the present study 
was to assess the clinical outcomes of HFRT for medically 




The Institution’s Ethical Review Board of the Seoul National 
University Hospital, Seoul, Korea, approved this retrospective 
study. Between September 2005 and August 2011, 26 patients 
underwent HFRT with radical aim for NSCLC at the Seoul 
National University Hospital, Seoul, Korea. Inclusion criteria 
were: 1) histologically or clinically diagnosed primary NSCLC; 
2) clinical stage T1-3N0 (American Joint Committee on Cancer 
Cancer Staging, 7th edition); 3) completion of hypofractionated 
radiotherapy with radical aim; and 4) inoperable status due 
to medical contraindication or refusal of surgery. Of the 26 
patients, 23 were considered to be medically inoperable due 
to medical conditions such as chronic pulmonary disease, 
advanced age, or other chronic illnesses. The remaining 3 
patients refused surgery. 
In all patients, the clinical work-up included a detailed 
medical history, physical examination, complete blood count, 
liver function test, renal function test, pulmonary function test, 
and computed tomography (CT) of the chest. All but 2 patients 
underwent positron emission tomography (PET). The 2 patients 
who did not undergo PET were examined by bone scan and 
sonography of abdomen for staging. Patient characteristics are 
shown in Table 1. 
2. Treatment 
All patients underwent a CT simulation in the treatment 
position. Tumor motion with breathing was monitored in all 
patients by fluoroscopy, and the amplitude of tumor motion 
was considered in RT planning. The delineation and planning 
for HFRT were CT-based. RT was administered with 6-MV X-ray 
with 3D-CRT technique using three to six coplanar and non-
coplanar beams. The gross tumor volume (GTV) encompassed 
the radiologically visible tumor on the mediastinal setting of 
simulation CTs. The contoured GTV was also modified with 
consideration of PET and CT lung window. Clinical target 
volume comprised GTV plus 10-15 mm anisotropic margins, 
and additional margins from clinical target volume were not 
adopted for planning target volume. Elective nodal irradiation 
was not adopted in all patients. 
The radiation dose ranged from 60 to 72 Gy (median, 70 Gy) 
and daily fraction sizes were 4 Gy, 3.13 Gy, and 3 Gy in 84.6%, 
7.7%, and 7.7% of patients, respectively. To compare the 
effects of various protocols with different fraction sizes and 
total doses, a biologically equivalent dose (BED) was adopted 
in a linear quadratic model. The α/β ratio was assumed to be 
10 for acute effects on normal tissues and tumors. BED ranged 
from 78.0 to 100.8 Gy (median, 94.5 Gy). BED > 90 Gy was 
reported in 13/26 patients. 
The median PTV was 125.3 mL (range, 11.5 to 450.5 mL) and 
the median GTV was 22.5 mL (range, 3.9 to 166.8 mL). The 
median V20 of both lungs was 15.9% (range, 6.5% to 28.2%). 
The maximal dose to the spinal cord ranged from 4 to 37 Gy. 
The V50 of the esophagus was below 5% in all but one patient. 
Neoadjuvant chemotherapy with paclitaxel and cisplatin was 
administered to 2/26 patients. The other 24 patients received 
radical radiotherapy alone.
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3. Evaluation of initial clinical response and toxicity
In terms of response criteria, a complete response (CR) was 
defined as disappearance of all measurable disease and the 
absence of new lesions for at least 4 weeks. For measurable 
disease, a partial response (PR) was defined as a 4-week 
reduction of greater than 30% of the sum of the diameters 
of the cross-sectional diameters of all measurable lesions. 
Progressive disease (PD) was defined as either a 4-week 
increase of greater than 20% of the sum of the diameters of 
the cross-sectional diameters of all assessable lesions or the 
appearance of new lesions. Stable disease (SD) was defined 
when there was neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD [15]. Acute and late 
toxicities were evaluated according to the Radiation Therapy 
Oncology Group/European Organization for the Treatment of 
Cancer scale [16]. 
4. Statistical analysis
Overall survival (OS), progression-free survival (PFS), local 
control (LC), and locoregional-free survival (LRFS) were 
calculated as the interval from the first date of treatment to 
the date of death or last follow-up, any progression detection, 
tumor progression within the radiation portal, and any failure 
within the regional lymph node stations and ipsilateral lung.
Survival curves were generated by the Kaplan-Meier method 
and univariate survival comparisons were performed using 
the log-rank test. Multivariate analyses were conducted using 
a Cox proportional hazards model with a backward stepwise 
selection procedure. A p-value of <0.05 indicated statistical 
significance. 
Results
The median follow-up time for surviving patients was 21 
months (range, 13 to 49 months). The mean overall treatment 
duration was 24 days. CR occurred in 2 patients (7.7%), PR in 
12 (46.2%), SD in 9 (34.6%). PD due to distant metastasis was 
observed in 3 patients (11.5%). The overall response rate was 
53.9%, and the initial local control rate was 100%. The median 
OS of all patients was 27.8 months. Two-year OS, PFS, LC, 
and LRFS were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. 
Relapses after treatment occurred in 9 patients during the 
follow-up period. The initial sites of failure were as follows: 3 
local only, 2 regional only, 1 local and regional, and 3 local and 
distant.
Univariate analysis of prognostic factors on clinical outcome 
is shown in Table 2. Age (>75 vs. ≤75 years) was a significant 
prognostic factor correlated with OS. BED (>90 vs. ≤90 Gy) 
was significantly related to PFS, LC, and LRFS. Fig. 1 illustrates 
the PFS and LC curves for each group. T stage was also a 
significant prognostic factor in LC. In multivariate analysis, 
BED (>90 vs. ≤90 Gy) was an independent prognostic factor 
predicting PFS (p = 0.025; hazard ratio [HR], 6.04; 95% 
confidence interval [CI], 1.25 to 29.2), LC (p = 0.046; HR, 9.27; 
95% CI, 1.04 to 82.9), and LRFS (p = 0.022; HR, 6.29; 95% 
CI, 1.30 to 30.38). No factors significant to OS were found in 
multivariate analysis. 
Table 1. Patient and treatment characteristics
Characteristic Value (%)
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ECOG, the Eastern Cooperative Oncology Group; FEV1, forced 
expiratory volume in 1 second; GTV, gross tumor volume; PTV, 
planning target volume; RT, radiotherapy; BED, biologically 
equivalent dose using a linear quadratic model, and the α/β ra-
tio was 10 for acute effects on normal tissues and tumors.
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Table 2. Univariate analysis of factors affecting clinical outcome



































































































































Values are presented as percentage of patient. A p-value was analyzed by log rank test. 
OS, overall survival; PFS, progression-free survival; LC, local control; LRFS, locoregional-free survival; ECOG, the Eastern Cooperative 
Oncology Group; FEV1, forced expiratory volume in 1 second; GTV, gross tumor volume; BED, biologically equivalent dose using a lin-
ear quadratic model, and the α/β ratio was 10 for acute effects on normal tissues and tumors.
Fig. 1. (A) Progression-free survival and (B) local control between the subgroups with biologically equivalent dose (BED) using a linear 
quadratic model, and the α/β ratio was 10 for acute effects on normal tissues and tumors. Solid line, BED > 90 Gy; dotted line, BED ≤ 
90 Gy.
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Among acute toxicities, grade 2 lung toxicities occurred 
in one patient and grade 2 esophagus toxicity occurred in 
one patient. Among late toxicities, one patient experienced 
grade 2 late lung toxicity, and one patient experienced grade 
2 esophagus toxicity (stricture). V50 and maximal dose of 
esophagus in the patient reporting grade 2 esophageal toxicity 
was 38.6% and 62 Gy, respectively. The fraction size and BED 
in the patient reporting grade 2 esophageal toxicity were 4 Gy 
and 100 Gy, respectively. No patient showed grade 3 toxicity in 
the acute or late phase. 
Discussion and Conclusion
The purpose of this study was to evaluate the clinical 
outcomes of HFRT for medically inoperable patients with early 
stage NSCLC and to evaluate prognostic factors. A 2-year OS 
of 54.3%, 2-year PFS of 61.1%, 2-year LC of 74.6%, and 2-year 
LRFS of 61.9% were achieved; this outcome was comparable 
with results from previous HFRT reports (2-year OS of 50-
60%, 2-year LC of 63-76%), but PFS was superior to those 
reported in previous studies (2-year PFS of 38-40%) [10-
14]. Local failure was the predominant pattern, as in previous 
studies of radical radiotherapy in early stage NSCLC [3,11,17]. 
The patterns of failure in these patient groups emphasize the 
importance of local control. For the control of NSCLC, it has 
been suggested that an overall treatment period shorter than 
kick-off time (Tk) (less than 4 weeks) has advantages over 
simple dose escalation with conventional fractions [10]. SABR 
with a large fraction size can achieve favorable local control 
for early stage NSCLC, which makes it the current standard 
treatment for medically inoperable patients [1,6-8]. 
However, SABR requires highly intensive and qualified 
resources in terms of all human, physical, and financial aspects 
[9]. In a 2011 survey in the United States, 46.1% of responding 
physicians did not use SABR and only 39% of small hospitals 
with one physician adopted SABR [18]. A survey in Japan 
also reported that 44% of replying institutions did not utilize 
SABR [19]. The ability to transfer patients to other hospitals 
far from patient residences is limited in cases of poor medical 
status. Although the number of hospitals using SABR is 
increasing, alternatives to SABR are necessary for practical 
reasons. In addition, for patients with large or centrally located 
tumors SABR may be limited by risk of toxicities [20]. In the 
current study, 8 patients with central tumors received HFRT. 
Among them, acute and late grade 2 esophageal toxicity were 
reported in 1 patient who received high dose HFRT with 4 Gy 
per fraction and BED 100 Gy. Although total dose and fraction 
size of HFRT should be adjusted for centrally located or large 
tumor, HFRT can be the second policy in patients ineligible for 
SABR.
Although HFRT is a reasonable option, radiotherapy fractions 
and total doses are very heterogeneous among the studies. 
Most fraction sizes are 3-3.5 Gy/fraction [10,11,13] and the 
results are comparable to those of the present study. However, 
Sandhu et al. [12] used 2.2-2.69 Gy/fractions in most patients 
(84.8%) and the resulting local control with a median value 
of 21.2 months was inferior to those reported in other studies 
[10-14]. In the current study, 4 Gy/fraction was utilized in 
84.6% of patients, and the toxicity profile was comparable to 
those reported in previous studies using 3-3.5 Gy/fractions. 
Cheung et al. [14] also showed that 4 Gy/fraction can be 
delivered safely with comparable tumor control rates. More 
accelerated fractionation with 4 Gy/fraction would lead to 
additional benefits in terms of tumor repopulation. In addition, 
radiotherapy is performed on an outpatient basis by most 
clinics, and the convenience and cost savings resulting from 
more accelerated radiation schedules with 4 Gy/fractions 
have practical advantages for patients susceptible to poor 
performance and comorbidities. 
Total dose was also a key factor to define in HFRT. The current 
study demonstrated that BED over 90 Gy is an independent 
significant prognostic factor in LC and PFS using a linear 
quadratic model, and an α/β ratio of 10 to determine acute 
effects on normal tissues and tumors. In previous studies using 
conventional fractionation, improved local PFS was observed 
for a subgroup of patients with no nodal disease receiving >73 
Gy 3D-CRT [21]. Onishi et al. [8] also demonstrated that BED 
≥100 Gy in SABR resulted in better LC and survival outcomes. 
These results are similar to the dose-response relationship 
shown in the present study. In terms of safety, no severe 
toxicities over grade 3 were observed in the present study, and 
low incidence of toxicities was also reported by Thirion et al. 
[13] (BED of HFRT, 93.6 Gy). Accordingly, HFRT with high BED 
over 90 Gy may improve tumor control without increasing 
toxicities, similar to SABR.
Interestingly, the PFS of the present study was superior to 
that of previous studies of HFRT [10-14]. The current study 
used PET for staging in 92.3% of patients, making this study 
distinct from previous studies [10-14]. It may be valuable 
to perform PET for pretreatment evaluation in NSCLC with 
clinically negative lymph nodes, because occult distant 
metastasis can be detected by whole body PET, and the 
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non-small cell lung cancer. J Korean Soc Ther Radiol Oncol 
2011;29:28-35. 
7. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radi-
ation therapy for inoperable early stage lung cancer. JAMA 
2010;303:1070-6.
8. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated 
high-dose irradiation for stage I nonsmall cell lung carci noma: 
clinical outcomes in 245 subjects in a Japanese multiinsti-
tutional study. Cancer 2004;101:1623-31.
9. Potters L, Kavanagh B, Galvin JM, et al. American Society for 
Therapeutic Radiology and Oncology (ASTRO) and American 
College of Radiology (ACR) practice guideline for the perfor-
mance of stereotactic body radiation therapy. Int J Radiat 
Oncol Biol Phys 2010;76:326-32.
10. Bonfili P, Di Staso M, Gravina GL, et al. Hypofractionated 
radical radiotherapy in elderly patients with medically ino-
perable stage I-II non-small-cell lung cancer. Lung Cancer 
2010;67:81-5.
11. Faria SL, Souhami L, Portelance L, et al. Absence of toxicity 
with hypofractionated 3-dimensional radiation therapy for 
inoperable, early stage non-small cell lung cancer. Radiat 
Oncol 2006;1:42.
12. Sandhu AP, Messer K, Fuster MM, et al. Hypofractionated 
radiotherapy for stage I non-small cell lung carcinoma in 
patients aged 75 years and older. J Cancer Ther 2011;2:167-71. 
13. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for 
non-small-cell lung cancer with accelerated hypofractionated 
three-dimensional conformal radiation therapy. Radiother 
Oncol 2004;71:163-6.
14. Cheung PC, Yeung LT, Basrur V, Ung YC, Balogh J, Danjoux CE. 
Accelerated hypofractionation for early-stage non-small-cell 
lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1014-23. 
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline 
(version 1.1). Eur J Cancer 2009;45:228-47.
16. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation 
Therapy Oncology Group (RTOG) and the European Organi-
zation for Research and Treatment of Cancer (EORTC). Int J 
Radiat Oncol Biol Phys 1995;31:1341-6. 
17. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in 
technically operable, medically inoperable, early-stage (I/II) 
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 
54:119-30. 
18.  Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A survey 
of stereotactic body radiotherapy use in the United States. 
Cancer 2011;117:4566-72.
19. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic 
body radiation therapy in Japan by the Japan 3-D Conformal 
External Beam Radiotherapy Group. Int J Radiat Oncol Biol 
negative predictive value for mediastinal lymph node is as high 
as 95% [22]. The benefits of LC after HFRT may improve PFS 
due to pretreatment work-up. However, interpretations of our 
results are limited because by the nature of small retrospective 
analysis. Our sample was small in part due to the limitations 
of HFRT. Therefore, the specific radiation dose schedule 
recommended in this paper should be interpreted with 
caution. However, HFRT is currently considered an alternative 
to SABR, so large prospective trials of HFRT might be difficult 
to perform.
HFRT with radical aim can yield satisfactory disease control 
with acceptable rates of toxicity in medically inoperable 
patients with early stage NSCLC. Although the resulting tumor 
control was inferior to that achieved by SABR, HFRT can be 
an alternative option for clinics and patients ineligible for 
SABR. BED over 90 and 4 Gy per fraction may be appropriate 
for HFRT, but the optimal radiation dose of HFRT should be 
confirmed by additional large-scale studies.
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